6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Cancer Research
Natalia IssaevaThomas Helleday

Abstract

Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors were tested for these tumors in clinical trials. In a screen for novel drugs that selectively kill BRCA2-defective cells, we identified 6-thioguanine (6TG), which induces DNA double-strand breaks (DSB) that are repaired by HR. Furthermore, we show that 6TG is as efficient as a PARP inhibitor in selectively killing BRCA2-defective tumors in a xenograft model. Spontaneous BRCA1-defective mammary tumors gain resistance to PARP inhibitors through increased P-glycoprotein expression. Here, we show that 6TG efficiently kills such BRCA1-defective PARP inhibitor-resistant tumors. We also show that 6TG could kill cells and tumors that have gained resistance to PARP inhibitors or cisplatin through genetic reversion of the BRCA2 gene. Although HR is reactivated in PARP inhibitor-resistant BRCA2-defective cells, it is not fully restored for the repair of 6TG-induced lesions. This is likely to be due to several recombinogenic lesions being formed after 6TG. We show that BRCA2 is also required for survival from mismatch repair-independent...Continue Reading

References

Mar 26, 1992·Nature·M S Satoh, T Lindahl
Jan 1, 1991·Mutation Research·B G BoyesR Stapley
Aug 17, 1999·International Journal of Cancer. Journal International Du Cancer·M SantarosaA Viel
Mar 10, 2001·Molecular Cell·M E MoynahanM Jasin
Jul 12, 2001·Proceedings of the National Academy of Sciences of the United States of America·F XiaS N Powell
Jan 5, 2002·Molecular and Cellular Biology·Maria Kraakman-van der ZwetMalgorzata Z Zdzienicka
Apr 23, 2002·Nature Genetics·Hanne Meijers-HeijboerUNKNOWN CHEK2-Breast Cancer Consortium
Aug 22, 2003·Nucleic Acids Research·Niklas SchultzThomas Helleday
Nov 14, 2003·Mutagenesis·Maria Kraakman-van der ZwetMałgorzata Z Zdzienicka
Jan 25, 2005·Nature Cell Biology·Claus Storgaard SørensenThomas Helleday
Apr 29, 2006·Mutation Research·Wouter W WiegantMałgorzata Z Zdzienicka
Jul 13, 2006·Nature Genetics·Anthony RenwickNazneen Rahman
Jan 4, 2007·Nature Genetics·Nazneen RahmanMichael R Stratton
Jan 4, 2007·Nature Genetics·Bing XiaJohan P de Winter
Jul 10, 2007·Cancer Research·Kazuhiko YamaneTimothy J Kinsella
Jul 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Xiaoling LiuJos Jonkers
Feb 12, 2008·Nature·Stacey L EdwardsAlan Ashworth
Apr 17, 2008·Cancer Research·Elizabeth M SwisherToshiyasu Taniguchi
Oct 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sven RottenbergJos Jonkers
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono

❮ Previous
Next ❯

Citations

Jul 14, 2012·Breast Cancer Research and Treatment·Soley Bayraktar, Stefan Glück
Aug 9, 2011·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Chenghui HuangZhiqiang Qin
Nov 3, 2011·Current Oncology Reports·Marcia Hall, Gordon Rustin
Nov 10, 2013·Nature Medicine·Christopher J Lord, Alan Ashworth
Aug 25, 2012·Nature Reviews. Cancer·Peter Bouwman, Jos Jonkers
Jun 28, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alpna TyagiRobert A Sclafani
Aug 9, 2011·Hereditary Cancer in Clinical Practice·Evgeny N Imyanitov, Vladimir M Moiseyenko
Feb 1, 2011·Journal of Molecular Cell Biology·Amal Aly, Shridar Ganesan
Nov 8, 2011·Trends in Pharmacological Sciences·Alberto Chiarugi
Feb 9, 2011·Current Problems in Cancer·Marcie K Weil, Alice P Chen
Oct 12, 2010·Seminars in Cancer Biology·Jean-Sébastien Hoffmann, Christophe Cazaux
Apr 23, 2013·The FEBS Journal·Torun EkbladAntonio Macchiarulo
Jan 6, 2011·Cancer Science·Kiranjit K DhillonToshiyasu Taniguchi
Jun 18, 2014·International Journal of Radiation Biology·Eniko HocsakArpad Boronkai
Jul 16, 2014·Biochimica Et Biophysica Acta·Barbara Lupo, Livio Trusolino
Nov 6, 2015·Science Translational Medicine·Daniel R CarterGlenn M Marshall
Nov 16, 2011·Therapeutic Advances in Medical Oncology·M Javle, N J Curtin
Oct 24, 2017·International Journal of Molecular Sciences·Robert CornelisonCharles N Landen
Mar 22, 2016·Biomarkers in Cancer·Bratati GangulyKim M Hirshfield
Jan 20, 2012·Nature·Christopher J Lord, Alan Ashworth
Jan 24, 2019·Journal of Cellular and Molecular Medicine·Xuan JiangZhenyu Zhang
Oct 13, 2011·British Journal of Cancer·M Javle, N J Curtin
Oct 23, 2016·Oncotarget·Cyril GaryNatalia Issaeva
Oct 6, 2020·Frontiers in Cell and Developmental Biology·Maddison RoseEmma Bolderson
Jun 20, 2017·Molecular Medicine Reports·Aleksandra M GorniewskaAneta Bialkowska
Sep 26, 2017·Environmental and Molecular Mutagenesis·Michael D WyattDouglas L Pittman
Jan 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shivaani KummarJames H Doroshow
Jun 18, 2017·Molecular Cancer Therapeutics·Amy DréanChristopher J Lord

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.